Recently, the Category 1 innovative drug Iruplinalkib Tablets (Chinese trade name: 启欣可) of Qilu Pharmaceuticals Co., Ltd is approved by China NMPA. It is indicated for the treatment of anaplastic lymphoma kinase (ALK) positive and locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have been treated with crizotinib and experienced disease progression or who are crizotinib -resistant.

　　Iruplinalkib is an ALK inhibitor that can inhibit the phosphorylation of ALK and c-ros oncogene 1 (ROS1) kinase, thereby blocking the activation of downstream signaling pathway proteins such as ERK, STAT5, and AKT, and further inducing tumor cell death (apoptosis). The marketing of this drug provides new treatment options for ALK positive locally advanced or metastatic NSCLC patients.